Pentasa
Indicated to manage inflammatory bowel disease, developed to alleviate intestinal inflammation.
Strengths: 400mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Mesalazine Granules; Salofalk
- Therapeutic class
5-Aminosalicylic Acid Derivative
- Pharmacological class
Aminosalicylate
- Precautions and warnings
monitor renal function; may cause blood dyscrasias
- Minor side effects
headache; abdominal pain; diarrhoea; nausea
- Moderate side effects
rash; fever; alopecia
- Dosage forms
Prolonged-release tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Ferring Pharmaceuticals
- Onset Time
1–2 weeks
- Duration
24 hours
- Storage instructions
Store below 25°C.
- Drug interactions
azathioprine; mercaptopurine
- Pregnancy and breastfeeding
Pregnancy: Use with caution. Breastfeeding: Use with caution; monitor infant.
Contraindications
hypersensitivity to salicylates; severe renal impairment; severe hepatic impairment
Serious side effects
nephrotoxicity — requires immediate medical attention; blood dyscrasias — requires immediate medical attention
Patient summary
Indicated to manage inflammatory bowel disease, developed to alleviate intestinal inflammation.
Mechanism of action
Mesalamine is an aminosalicylate that acts locally in the gastrointestinal tract, inhibiting the production of prostaglandins and leukotrienes, which reduces mucosal inflammation in conditions like ulcerative colitis.
Pentasa
Indicated to manage inflammatory bowel disease, developed to alleviate intestinal inflammation.
Editorial Notes
- Active ingredient(s): Mesalamine
- Listed indication(s): Ulcerative Colitis, Crohn’s Disease
Available option
- 90 tablets - 400 mg726-400-mg-3758